The application of a PDE10A inhibitor in the subacute phase of stroke, after cell death and secondary injury have taken place, provides an opportunity for selective manipulation of neuronal signaling systems associated with synaptic plasticity particularly strong in the basal ganglia or striatum. The gene discussed is PDE10A; the disease is Stroke.